BBIO250117C65000
- 0.75
- 0.000.00%
BridgeBio Pharma Newsroom
Citi Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45
Optimistic Growth Projections and Financial Adjustments Justify Buy Rating for BridgeBio Pharma
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45
S&P 500 Futures Drop In Premarket Trading; Sportradar Group, Cytokinetics Lead
BridgeBio Pharma Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $50
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Piper Sandler Remains a Buy on BridgeBio Pharma (BBIO)
Optimistic Buy Rating for BridgeBio Pharma Due to Strong Launch and Strategic Initiatives
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $49
Express News | HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $49 Price Target
BridgeBio Pharma Analyst Ratings
BridgeBio Pharma's Growth Prospects Bolstered by Acoramidis Approval and Promising Pipeline
Bridgebio Pharma Says Committee For Medicinal Products For Human Use (CHMP) Recommends Marketing Authorization In European Union For Acoramidis For The Treatment Of Wild-type Or Variant Transthyretin Amyloidosis In Adult Patients With Cardiomyopathy...
Express News | EMA's Chmp: Adopted Positive Opinion for Beyonttra (Acoramidis)
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)
Unnatural Products Announces BridgeBio Exercises Option To License Macrocyclic Peptide Candidates Discovered Using UNP's AI-Enabled Massively Parallel Chemistry Platform
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma Receives Buy Rating Following Attruby's FDA Approval and Strategic Milestones